Prurigo Nodularis - Pipeline Insight, 2024

This “Prurigo nodularis - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Prurigo nodularis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Prurigo nodularis Understanding

Prurigo nodularis: Overview

Prurigo nodularis (PN) is a skin disease that causes hard, itchy lumps (nodules) to form on the skin. The itching (pruritus) can be intense, causing people to scratch themselves to the point of bleeding or pain. Scratching can cause more skin lesions to appear. The itching is worsened by heat, sweating, or irritation from clothing.[4] In some cases, people with PN have a history of other diseases including eczema (atopic dermatitis), lymphoma, HIV infection, severe anemia, or kidney disease.

The exact cause of PN is unknown. Although scratching is known to cause more nodules to appear, it is unclear what causes the itching to develop in the first place.

Symptoms
The main symptom of prurigo nodularis (PN) is the formation of hard, very itchy lumps (nodules) on the skin. The nodules can range in size from very small to about half an inch in diameter. The nodules often have a rough, dry top and can range in number from a few to hundreds. Nodules most commonly form on the outer arms, shoulders, and legs. Nodules can also form on the neck and trunk, and they rarely form on the face and palms. They may be lighter or darker in color than the surrounding skin. Scarring may occur after nodules begin to heal.

Diagnosis
Prurigo nodularis may be suspected when a person has signs and symptoms of the disease including intensely itchy skin and the development of nodules on the skin. In some cases, a doctor may wish to perform a skin biopsy to look for signs of the disease such as thickened nerves in the skin. After the diagnosis has been confirmed, other tests such as a blood test and tests of liver and kidney function may be recommended to rule out underlying causes of the disease.

Treatment
Prurigo nodularis (PN) can be challenging to treat because people with the disease may respond to treatments differently. Due to the intensity of the itch, people with PN may try several different treatments without receiving much relief. Some people may try all current treatments available without receiving complete relief. For most people, a combination of several treatments may need to be tried to find out what will work best.

The most commonly used treatments for PN are:

• Corticosteroid creams that are applied to the nodules (topical) and covered with special bandages that are air- and water-tight
• Corticosteroid injections into the nodules
• Ointments with menthol or phenol to cool and soothe itchy skin
• Capsaicin cream
• Oral corticosteroids
• Oral antihistamines
• Selective serotonin reuptake inhibitors (SSRIs)

Prurigo nodularis Emerging Drugs Chapters

This segment of the Prurigo nodularis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Prurigo nodularis Emerging Drugs

Nemolizumab: Chugai/Galderma Nemolizumab was discovered by Chugai, and uses Chugai’s proprietary antibody engineering technology ACT-Ig, which can extend the biological half-life of antibodies in blood. IL-31 has been identified as a pruritogenic cytokine, and reported to be associated with pruritus in many diseases including atopic dermatitis and hemodialysis. Nemolizumab is designed to inhibit the activities of IL-31 by competitively blocking binding with its receptor. It is currently in phase III stage ofdevelopment.

Nalbuphine ER: Trevi Therapeutics Trevi is developing nalbuphine ER in a range of indications for which patients have few treatment options. With its dual mechanism of action, acting as both an antagonist (blocker) to the mu opioid receptor and as an agonist (activator) to the kappa opioid receptor, Nalbuphine ER has the potential to significantly improve the quality of life of patients suffering from serious neurologically mediated conditions by targeting the central and peripheral nervous systems. It is currently in phase III stage of development.

Vixarelimab: Kiniksa Pharmaceuticals Vixarelimab is Monoclonal antibody inhibiting signaling through oncostatin M receptor beta (OSMRß). Vixarelimab inhibits signaling of interleukin-31 (IL-31) and oncostatin M (OSM), 2 key cytokines implicated in inflammation, pruritus, and fibrosis. It is currently in phase II stage of development.

Prurigo nodularis: Therapeutic Assessment

This segment of the report provides insights about the different Prurigo nodularis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Prurigo nodularis

There are approx. 5+ key companies which are developing the therapies for Prurigo nodularis. The companies which have their Prurigo nodularis drug candidates in the most advanced stage, i.e. phase III include Chugai/Galderma and others

Phases

This report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Prurigo nodularis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Prurigo nodularis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Prurigo nodularis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Prurigo nodularis drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Prurigo nodularis R&D. The therapies under development are focused on novel approaches to treat/improve Prurigo nodularis.

• In July 2016, Chugai Pharmaceutical and Galderma Pharma S.A. announced that they have entered into a global license agreement for “nemolizumab” (CIM331). Under the agreement, Chugai will grant Galderma an exclusive license for the development and marketing of nemolizumab worldwide, with the exception of Japan and Taiwan.

In April 2020, Kiniksa Pharmaceuticals announced data from the phase IIa clinical trial in prurigo nodularis for vixarelimab (KPL-716). The trial met its primary efficacy endpoint: the reduction in weekly-average WI-NRS from baseline at Week 8 was statistically significantly greater in patients who received vixarelimab versus those who received placebo.

Prurigo nodularis Report Insights

• Prurigo nodularis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Prurigo nodularis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Prurigo nodularis drugs?
• How many Prurigo nodularis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Prurigo nodularis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Prurigo nodularis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Prurigo nodularis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Menlo Therapeutics
• Galderma R&D
• Kiniksa Pharmaceuticals
• Sanofi
• Maruho

Key Products

• Serlopitant
• Nemolizumab
• KPL-716
• SAR231893
• M118103

This product will be delivered within 1-3 business days.